BioCryst (BCRX) Slammed After Withdrawing BCX5191 IND
Tweet
Share
E-mailGet Alerts BCRX Hot Sheet
Join SI Premium – FREE
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) is getting slammed Wednesday, following an announcement on Tuesday that it has withdrawn ts Investigational New Drug application (IND) for the antiviral nucleoside, BCX5191, following a discussion with the U.S. Food and Drug Administration (FDA).
Shares are down about 30 percent Wednesday morning on heavy volume.
Shares are down about 30 percent Wednesday morning on heavy volume.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA authorizes 11 ZYN Ultra nicotine pouches for Philip Morris
- AbbVie lung cancer drug data shows high response rates at WCLC 2026
- FDA grants Nuvation Bio fast track status for brain cancer drug
Create E-mail Alert Related Categories
FDA, Momentum MoversSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
